Screener
Beam Therapeutics BEAM Debt Issuance Proceeds
Debt Issuance Proceeds at other companies
Other financials
Where this comes from
Reported directly by Beam Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromDebtNetOfIssuanceCosts.
The source filing: Beam Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:22 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210338
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Proceeds from issuance of common shares and pre-funded warrants, net of issuance costs | — | 471,159 |
| Proceeds from issuances of stock under ESPP | 1,510 | 1,501 |
| Proceeds from exercise of stock options | 2,025 | 719 |
| Proceeds from the issuance of debt, net of fees paid to lender | 93,886 | — |
| Payments of debt issuance costs | (813) | — |
| Net cash provided by (used in) financing activities | 96,608 | 473,379 |
| Net change in cash, cash equivalents and restricted cash | (6,636) | 244,406 |
| Cash, cash equivalents and restricted cash—beginning of period | 301,620 | 290,111 |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Beam Therapeutics's debt issuance proceeds?
- Beam Therapeutics (BEAM) reported debt issuance proceeds of $93.89M in Q1 2026.
- What does debt issuance proceeds mean?
- Cash received from issuing bonds, notes, term loans, and other debt instruments in the capital markets or from bank lending.
Ask your AI about Beam Therapeutics's debt issuance proceeds.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude